Copilot
Your everyday AI companion
About 12,400,000 results
  2. People also ask
    Is GlaxoSmithKline (GSK) a good stock to buy?
    Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of p1,530.00. Graham Parry has given his Sell rating due to a combination of factors impacting GlaxoSmithKline’s financial outlook.

    GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market …

    markets.businessinsider.com
    Did GlaxoSmithKline receive income tax refund?
    Shares of GlaxoSmithKline Pharmaceuticals Ltd ended at ₹2,836.20, up by ₹53.90, or 1.94%, on the BSE. Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order issued by the Income Tax Department.

    GlaxoSmithKline Pharma gets big income tax refund

    cnbctv18.com
    Will GlaxoSmithKline lose exclusivity exposure in 2027?
    He points to GlaxoSmithKline’s earnings per share growth rate, which is predicted to be below the sector average between 2025 and 2028. Furthermore, the company faces significant loss of exclusivity exposure, particularly with Dolutegravir constituting roughly 30% of the company’s operating income by 2027.

    GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market …

    markets.businessinsider.com
    Why has Graham Parry rated GlaxoSmithKline a sell?
    Graham Parry has given his Sell rating due to a combination of factors impacting GlaxoSmithKline’s financial outlook. He points to GlaxoSmithKline’s earnings per share growth rate, which is predicted to be below the sector average between 2025 and 2028.

    GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market …

    markets.businessinsider.com
    Feedback
  3. GSK
    https://www.gsk.com/en-gb/media/pres…

    Press releases | GSK

    WEBGSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive …

    • Estimated Reading Time: 2 mins
    • GSK
      https://us.gsk.com/en-us/media/press-re…

      Press releases | GSK US

      WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at …

      • Estimated Reading Time: 9 mins
      • GSK
        https://us.gsk.com/en-us/media/press-releases/us...

        US FDA approves GSK’s AREXVY, the world’s first respiratory …

      • Reuters
        https://www.reuters.com/business/healthc…

        GSK's experimental drug shows promise in reducing …

        WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker expects to...

        Tags:
        Reuters
        Experimental drug
      • gsk.com
        https://news.gsk.com

        GSK News

      • GSK
        https://us.gsk.com/en-us/media/press-releases/gsk...

        GSK announces cap of $35 per month on U.S. patient out-of …

        Tags:
        GSK US
        Chronic obstructive pulmonary disease
      • CNBC
        https://www.cnbc.com/2024/01/31/gsk-posts-blowout...

        GSK posts blowout RSV vaccine sales, raises outlook | CNBC

        Tags:
        GSK
        GlaxoSmithKline
      • Reuters
        https://www.reuters.com/business/healthc…

        GSK completes acquisition of Aiolos Bio for up to $1.4 …

        WEBLONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...

        Tags:
        GSK
        Reuters
      • GSK
        https://www.gsk.com/en-gb/media/pres…

        GSK delivers strong 2023 performance and upgrades …

        WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 …

      • GSK
        https://www.gsk.com/en-gb/media/press-releases/gsk...

        GSK to acquire clinical-stage biopharmaceutical company …

        Tags:
        Affinivax Acquisition
        Affinivax Inc Founders
        Affinivax Stock